First oral drug approved for postpartum depression

Like other forms of depression, postpartum depression is characterized by sadness and/or loss of interest in activities once enjoyed, as well as a decreased ability to feel joy.

The U.S. Food and Drug Administration (FDA) has approved “Zurzuvae” (zuranolone), the first oral medication for the treatment of postpartum depression in adults. The recommended daily dose of “Zurzuvae” is 50 mg once a day for 14 days in the evening… + read more

Biomarkers discovered in women with postpartum depression and anxiety

Many women experience significant symptoms of mood and anxiety disorders after childbirth that can interfere with overall health, daily activities, and family life. + read more

Basic work of medical personnel during pregnancy and childbirth

In 2020, obstetrics and gynecology professionals received more than 7,345,000 consultations in Spanish hospitals. + read more

Exposure to green spaces may reduce risk of postpartum depression

Developing environments with extensive green spaces while allowing for physical activity is one way to promote the well-being of certain populations, especially new mothers who are at risk for postpartum depression. + read more

Postpartum hemorrhage is the leading cause of maternal death worldwide

Time is of the essence for an adequate response to postpartum hemorrhage, so in this sense a game changer should be promoted for maternal care. + read more

Researchers to analyze determinants when dealing with labor pain

They will do so in a scientific project to analyze fertility assistance in an international, multicenter and multicultural setting. + read more

New discovery of genetic factors for preterm birth

The process that precedes human birth is so critical that specific studies are needed to understand the circumstances surrounding the induction process. + read more

Source link

Leave a Comment